Study reports the balance between serotonin and dopamine may be a risk factor for a person developing social anxiety disorder.
Neuroimaging study reveals decreased levels of the SV2A protein in synapses in patients with schizophrenia. The decrease in the protein could underlie the cognitive difficulties experienced by those with schizophrenia and provide new targets for treatment.
Mu-opioid receptor (MOR) levels are significantly reduced in the striatum in those with schizophrenia. A lack of MOR system stimulation contributes to negative feelings, such as a lack of motivation and anhedonia, associated with the condition. Increasing MOR levels could help to reduce some of the symptoms of schizophrenia.
A new, non-invasive brain stimulation treatment shows promise in enhancing memories and cognitive function in those with Alzheimer's disease. Transcranial electromagnetic treatment (TEMT) increases functional connectivity within the cingulate cortex. TEMT is also able to penetrate the brain to break up amyloid-beta and tau deposits, slowing the progression of Alzheimer's disease.
A new blood test for Alzheimer's disease is up-to 94% accurate at predicting dementia before symptoms appear. The test's accuracy is increased when genetic predisposition and age are taken into account. The new test may eventually replace PET neuroimaging, currently considered the gold standard, for early detection of Alzheimer's.
A link between liver dysfunction and Alzheimer's disease has been discovered. The findings add to the understanding of the role metabolic dysfunction plays in the neurodegenerative disease.
A neuroimaging study on house sparrows reveals changes in the dopaminergic system could be a physiological mechanism underlying the negative behavioral effects of chronic stress. The findings shed light on stress and resilience in wildlife and humans.
A novel PET neuroimaging tracer detects abnormal inflammation in the cerebral gray matter of patients with secondary progressive multiple sclerosis.
A new blood test to detect biomarkers for Alzheimer's disease is set to undergo trials in the Fall. The test will be able to identify traces of amyloid beta in blood samples with a high degree of accuracy.
Sleep disruptions during middle age may be a potential biomarker for developing Alzheimer's disease later in life. Researchers found those who experienced sleep problems in their 40s and 50s had more amyloid beta accumulation in their brains later in life. Those whose sleep problems started in their 50s and 60s had increased levels of tau. Additionally, higher levels of tau were discovered in the brains of those who lacked synchronized brain waves associated with a good night's sleep.
Smokers may have reduced neuroimmune function compared to their non-smoking peers. Researchers report restoring the immune system may benefit smokers. Immune dysfunction is linked to cognitive dysfunction.